BioNTech SE - ADR vs ProShares UltraPro S&P500 — how do they compare? BioNTech SE - ADR trades at $92.8 (market cap $23.31B), while ProShares UltraPro S&P500 trades at $154.46. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | UPRO | |
|---|---|---|
Market Cap | $23.31B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $119.34 | $155.10 |
52-Week Low | $83.89 | $89.29 |
Enterprise Value | $6.60B | — |
Trailing returns across standard periods
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →